Sigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development
July 19, 2021 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A
July 09, 2021 07:30 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
Sigilon Therapeutics Appoints Brooke Story, M.B.A., to its Board of Directors
June 16, 2021 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
Sigilon Therapeutics Appoints Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer
June 14, 2021 16:05 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
Sigilon Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 27, 2021 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
May 10, 2021 16:05 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
Sigilon Therapeutics to Present at the BofA Securities 2021 Healthcare Conference
May 06, 2021 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded...
Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting
April 27, 2021 16:30 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
April 08, 2021 07:00 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
March 18, 2021 16:05 ET
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...